Amplia Therapeutics Surpasses $2.5M SPP Target, Fuelling Key Cancer Trials
Amplia Therapeutics has successfully raised A$2.65 million through its Share Purchase Plan, exceeding expectations and bolstering funding for pivotal clinical trials of its lead drug narmafotinib.
- SPP raised A$2.65 million, surpassing original A$2.5 million target
- Total capital raising including placements reaches A$27.65 million
- Funds to support ACCENT and AMPLICITY clinical trials for narmafotinib
- Plans to accelerate pivotal phase 2b/3 trial in second half of 2026
- SPP completion contingent on shareholder approval at upcoming AGM
Capital Raising Success
Amplia Therapeutics Limited (ASX – ATX) has announced a successful close to its Share Purchase Plan (SPP), raising A$2.65 million; exceeding the initial target of A$2.5 million. This achievement is part of a broader capital raising initiative that includes institutional placements, collectively raising A$27.65 million. The additional funds come at a critical juncture as Amplia advances its clinical development programs.
Funding Clinical Progress
The proceeds from the capital raising will primarily support Amplia’s lead drug candidate, narmafotinib (AMP945), through ongoing ACCENT and AMPLICITY trials, as well as potential investigator-initiated studies. These trials target fibrotic cancers such as pancreatic and ovarian cancer, areas where Amplia’s Focal Adhesion Kinase (FAK) inhibitors show promise. The company aims to accelerate preparations for a pivotal phase 2b/3 trial slated for the second half of 2026, a key milestone that could significantly impact its clinical trajectory.
Shareholder Approval and Market Implications
The SPP shares are priced at A$0.18 each, reflecting a discount to recent trading prices to encourage participation. However, the completion of the SPP remains conditional on shareholder approval at Amplia’s Annual General Meeting scheduled for 27 August 2025. Assuming approval, new shares will be issued by the end of August, with trading commencing in early September. Amplia’s Managing Director, Dr Chris Burns, expressed gratitude for shareholder support, emphasizing the importance of this funding in sustaining clinical momentum.
Looking Ahead
With the capital raising secured, Amplia is now funded into 2027, providing a runway to advance its clinical programs without immediate funding concerns. The company’s focus will likely shift toward delivering clinical data and navigating regulatory pathways, which will be closely watched by investors. The absence of a shortfall offer indicates confidence in the current capital raise, but also leaves little room for additional immediate funding from this round.
Bottom Line?
Amplia’s successful capital raise sets the stage for critical clinical milestones, but shareholder approval remains the final hurdle.
Questions in the middle?
- Will shareholders approve the SPP and conditional placements at the upcoming AGM?
- How will upcoming clinical trial data influence Amplia’s valuation and investor sentiment?
- What are the company’s plans if the pivotal phase 2b/3 trial timelines shift or face regulatory challenges?
